Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker assays designed to improve the detection of systemic lupus erythematosus ...

Exagen Inc. achieves its 1,000,000th AVISE CTD test, enhancing autoimmune disease diagnosis and patient care. Exagen Inc. Celebrates Milestone of 1,000,000 AVISE CTD Tests Completed for Autoimmune ...

--Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus and rheumatoid arthritis ...

AVISE CTD (SLE/RA Diagnostic Test) Exagen’s flagship product is the AVISE CTD test , designed to diagnose connective tissue diseases (SLE, rheumatoid arthritis, etc.) .

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic ...

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform Nov. 14, 2024 4:30 PM ET Exagen Inc. (XGN) Q3: 2024-11-12 ...